Literature DB >> 6230305

Reactivity pattern of 15 HLA-Dw1 homozygous typing cells in primary mixed lymphocyte culture.

E M Schneider, U Krupp, S Marchal, C Rittner.   

Abstract

The Dw1 specificity was highly correlated with the serologically determined HLA-DR1 antigen in the Eighth International Histocompatibility Workshop 1980. By testing a large number of HLA-Dw1, DR1 defined homozygous typing cells (HTC) in a checkerboard primary mixed lymphocyte reaction, on a panel of about 30 HLA-DR1 heterozygous individuals, and in family segregation, three Dw1 "subtypes" could be defined in association with certain HLA-A, -B, and -C-antigens. HTC TA, FRI, and FRA carrying the HLA haplotypes A11, B35, Cw4 or A3, B35, Cw4 in the homozygous state gave positive typing results with most HLA-DR1 positive panel members and stimulated only four other Dw1 HTCs (SRR less than or equal to 35%). In contrast to this operationally "broad" specificity, Dw1-HTC-HEN (HLA-A2, B44, C-, homozygous) was non-stimulatory to all HTCs except one, but gave high responses against these, leading to the definition of a "narrow" specificity included in the "broad" one. Another such "narrow" specificity was represented by HTC FEE (HLA-A2, B27, Cw2 homozygous). Typing patterns with FEE were mostly different from those defined with other HTC. In family studies a specific typing pattern for this HTC could be shown to segregate with HLA. However, within some of these responses a contribution of the HLA haplotype in the trans position must be assumed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230305     DOI: 10.1007/bf00286510

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  25 in total

1.  Restimulation properties of cloned alloactivated lymphocytes: detection of a novel type of HLA-D/DR region determinant and allelic subtypes for HLA-Dw3 using cloned reagents.

Authors:  G Pawelec; A Rehbein; P Kahle; C Müller; P Wernet
Journal:  Hum Immunol       Date:  1981-07       Impact factor: 2.850

Review 2.  Cellular typing.

Authors:  B A Bradley; H Festenstein
Journal:  Br Med Bull       Date:  1978-09       Impact factor: 4.291

3.  Five HLA-D clusters associated with HLA-DR4.

Authors:  N L Reinsmoen; F H Bach
Journal:  Hum Immunol       Date:  1982-06       Impact factor: 2.850

4.  Population studies of HLA-linked SB antigens and their relative importance in primary MLC typing. Analysis of HLA-D homozygous typing cells and normal heterozygous populations.

Authors:  G Pawelec; S Shaw; M Schneider; M Blaurock; M Frauer; D Brackertz; P Wernet
Journal:  Hum Immunol       Date:  1982-11       Impact factor: 2.850

5.  HLA-DR, D recombination in a kidney transplant recipient.

Authors:  J R Oksenberg; A Amar; N Cohen; T Cohen; C Brautbar
Journal:  Hum Immunol       Date:  1982-02       Impact factor: 2.850

6.  T cell clones restricted to "hybrid" HLA-D antigens?

Authors:  G S Hansen; A Svejgaard; M H Claësson
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

7.  Allogeneic mixed lymphocyte reactions in humans: pretreatment of either the stimulator or the responder cell population with monoclonal anti-Ia antibodies leads to an inhibition of cell proliferation.

Authors:  R S Accolla; A Moretta; J C Cerottini
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

8.  Ia antigens on alloreactive T cells in man detected by monoclonal antibodies. Evidence for synthesis of HLA-D/DR molecules of the responder type.

Authors:  D J Charron; E G Engelman; C J Benike; H O McDevitt
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

9.  New HLA-D alleles associated with DR1 and DR2.

Authors:  N Suciu-Foca; M Godfrey; G Khan; K Woodward; C Rohowsky; E Reed; M Hardy; K Reemtsma
Journal:  Tissue Antigens       Date:  1981-03

10.  Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses.

Authors:  S Shaw; A H Johnson; G M Shearer
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.